Itraconazole in human aspergillosis revisited

Journal de Mycologie Medicale

Volumn 14, Issue 4 I, 2004, Pages 192-200

  Pierard G E ^a   Kharfi, M ^b   Salomon Neira, M D ^a,c   Kamoun, M R ^b   Pierard Franchimont C ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

Author keywords

Aspergillosis; Itraconazole; Mycosis; Pharmacodynamics; Pharmacokinetics; Triazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; NEUTROPENIA; REVIEW;

ANIMALIA; ASPERGILLUS;

EID: 11244266054     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Piérard GE, Arrese JA, Piérard-Franchimont C. Itraconazole. Expert Opin. Pharmacother 2000;1:287-304.
2. Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen AJ. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984;26:527-34.
3. Groll AH. Itraconazole-perspectives for the management of invasive aspergillosis. Mycoses 2002;45:48-55.
4. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26: 781-805.
5. Alexander BD. Prophylaxis of invasive mycoses in solid organ transplantation. Curr Opin Infect Dis 2002;15:583-9.
6. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses in solid organ transplantation. Curr Opin Infect Dis 2002; 15:569-74.
7. Ergin F, Arslan H, Azap A, Demirhan B, Karakayali H, Haberal M. Invasive aspergillosis in solid-organ transplantation: report of eight cases and review of the literature. Transpl Int 2003;16:280-6.
8. Bohme A, Ruhnke M, Buschheidt D, Karthaus M, Einsele H, Guth S. et al. Treatment of fungal infections in hematology and oncology guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology. Ann Hematol 2003;82:S133-S40.
9. Kontoyiannis DP, Chagua MR, Ramirez I, Prieto V. Locally invasive auricular aspergillosis after ear piercing in a neutropenic patient with leukemia. Am J Hematol 2003;73:296-7.
10. Panackal AA, Dahlman A, Keil KT, Peterson CL, Mascola L, Mirza S, et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 2003;75:1050-3.
11. Coleman JM, Hogg GC, Rosenfeld JV. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B. itraconazole, and radical surgery: case report and review of the literature. Neurosurgery 1995;36:858-63.
12. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species. Risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003;46:25-8.
13. Vanden Bossche H, Marichla P, Gorrens J, Geerts H, Janssen PA. Mode of action studies. Basis for the search of new antifungal drugs. Ann NY Acad Sci 1988;544:191-207.
14. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
15. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;35:111-80.
16. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987;9: S15-S32.
17. Arrese JE, De Doncker P, Odds F, Piérard GE. Reduction in the growth of non-dermatophyte molds by itraconazole: evaluation by the corneofungimetry bioassay. Mycoses 1998;41:461-5.
18. Espinel-Ingroff A: Comparison of the E-test with the NC-CLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol. 2001;39:1360-7.
19. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
20. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother 1997;41:1364-8.
21. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration effect relationships in vitro and in vivo. Pharmacotherapy 2001;27:133S-8S.
22. Manavathu IK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother 1998; 42:3018-21.
23. Patterson TF, Fothergill AW, Rinaldi MG. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother 1993;37:2307-10.
24. Van Cutsem J, Meulemans L, van Gerven F, Stynen D. Effect of tissue invasion and treatment with itraconazole or amphotericin B on galactomannan levels in plasma of guinea-pigs with experimental invasive aspergillosis. J Med Vet Mycol 1993;37:315-24.
25. Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battagia S, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994;38:1303-18.
26. Arrese JE, Delvenne P, Van Cutsem J, Piérard-Franchimont C, Piérard GE. Experimental aspergillosis in guinea pigs. Influence of itraconazole on fungaemia and invasive fungal growth. Mycoses 1994;37: 117-22.
27. Odds FC, Oris M, Van Dorsselaer P, van Gerven F. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agents Chemother 2000;44:3180-3.
28. Kaliamurthy J, Geraldine P, Thomas PAS. Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy. Mycoses 2003;119:854-8.
29. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43.
30. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003;188:305-19.
31. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001;47:333-40.
32. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997;40:401-14.
33. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA. In vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA network. European Research Group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol 1999;48: 1087-93.
34. Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999;12:213-9.
35. Osherov N, Kontoyiannis DP, Romans A, May GS. Resistance of itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P450 14 alpha demethylase gene, pdm A. J Antimicrob Chemother 2001;418:75-81.
36. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother 2002;46:556-7.
37. Barone JA, Moskovitz BI, Guarnieri J. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother 1998;42: 1862-5.
38. Van De Velde VJ, Van Peer AP, Heykants JJ. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacothrapy 1996;16:424-8.
39. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regiments using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591-600.
40. Stevens DA. Itraconazole in cylodextrin solution. Pharmacotherapy 1999;19:603-11.
41. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997;86: 147-62.
42. Heykants J, Michiels M, Meuldermans W. The pharmacokinetics of itraconazole in animals and man: an overview. In R.A. Fromtling, ed Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous Science Publ, Barcelona 1987:pp 223-249.
43. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole. Pharmacologic studies in animals and humans. Rev Infect Dis 1987;9:S43-S6.
44. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
45. Miyama T, Takanaga H, Matsuo H. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998;42:1738-44.
46. Warnock DW, Turner A, Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988;21:93-100.
47. Glasmacher A, Molitor E, Hahn C. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998;12:1338-43.
48. Prentice AG, Warnock DW, Johnson SA, Taylor PC, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995;36:657-63.
49. th International conference on Antimicrobial Agents and Chemotherapy, abstr. 1646. Am Soc Microbiol. Washington DC 1999:p 575.
50. Groll AH, Mickiene D, McEvoy M, Dad L, Townley E, Piscitelli S, et al. Safety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with HIV infection and oropharyngeal candidiasis. Antimicrob Agents Chemother 2002;46:2554-63.
51. Salez FS, Brichet A, Desurmont S, Grosbois JM, Wallaert B, Tonnel AB. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999;116:1665-8.
52. Stevens DA, Schwarz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62.
53. Kumar R, Singh P, Arora R, Gaur SN. Effect of itraconazole therapy in allergic bronchopulmonary aspergillosis. Saudi Med J 2003;24: 546-7.
54. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003;111:952-1.
55. Petrak RM, Pottage JC, Levin S. Invasive external otitis caused by Aspergillus fumigatus in an immunocompromised patient. J Infect Dis 1985;151:196-7.
56. Finer G, Greenberg D, Leibovitz E, Lieberman A, Shelef I, Kapelushnik J. Conservative treatment of malignant invasive external otitis caused by Aspergillus flavus with oral itraconazole solution in a neutropenic patient. Scand J Infect Dis 2001;34:227-9.
57. Bellini C, Antonini P, Ermanni S, Dolina M, Passega E, Bernasconi E. Malignant otitis externa due to Aspergillus niger. Scand J Infect Dis 2003;35:284-8.
58. th Int. Skin Ther. Symp, Brussels, Belgium 1996:pp 24-6.
59. Steinbach WJ, Stevens DA, Denning DW, Moss RB. Advances against aspergillosis. Clin Infect Dis 2003;37:S155-6.
60. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37:S157-87.
61. Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination? J Infect Dis 2003;187:1831-3.
62. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GJ. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982;61:109-24.
63. Wong PC, Fung SL, Lee J, Wong CF, Chau CH, Yew WW. Chronic necrotizing pulmonary aspergillosis. A report of 9 cases with analysis of clinical picture, risk factors and treatment for outcome correlation. Monaldi Arch Chest Dis 2001;56:202-7.
64. Buchet P, Pourriat JL, Dupont B. Aspergillose pulmonaire chronique nécrosante. Guérison sous itraconazole. Rean Soins Intens Med Urg 1989;5:17-9.
65. Elliott JA, Milne LJR, Cumming D. Chronic necrotising pulmonary aspergillosis treated with itraconazole. Thorax 1989;44:820-1.
66. Tasci S, Schafer H, Ewig S, Layer G, Gillissen A. Erfolgeriche Behandlung einer chronisch nekrotisierenden pulmonalen Aspergillose mit einer oralen Itraconazol-Laagzeittherapie. Dtsch Med Wschr 1999; 124:1419-22.
67. Arrese Estrada J, Pierard-Franchimont C, Soyeur-Broux M, Piérard GE. Cutaneous aspergillosis. Rev Med Liège 1991;46:92-7.
68. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study 1982-1987. Mycoses 1988;31:476-85.
69. De Doncker PRG, Scher RK, Baran RL, Decroix J, Degreef HJ, Roseeuw DI, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997;36;173-7.
70. Agarwal PK, Roy P, Das A. Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study. Ind J Ophthalmol 2001;49:173-6.
71. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
72. Viviani MA, Tortorano AM, Pagano A, Vigevani GM, Gubertini G, Cristina S, Assaisso ML, Suter F, Farina C, Minetti B. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 1990; 23:587-93.
73. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-14.
74. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97: 135-44.
75. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria. Arch Intern Med 1997;157:1857-62.
76. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:283-90.
77. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious diseases society of America. Clin Infect Dis 2000;30: 696-809.
78. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995;39:1907-12.
79. Bohme A, Just-Nubling G, Bergmann L, Shah PM, Stille W, Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1999;42:443-51.
80. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443-51.
81. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC invasive fungal infections cooperation group. J Infect 1998;37:173-80.
82. Popp AI, White MH, Quadri T, Walshe L, Armstrong D. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis 1999;3:157-60.
83. Rubin MA, Carroll Kc, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002;34:1160-1.
84. Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003;109:111-8.
85. Maertens J, Boogaerts M. Caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 2003;7:94-101.
86. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003;37:S188-24.
87. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-9.
88. Menichetti F, Del Favero A, Martino R. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with haematological malignancies. Clin Infect Dis 1999;28:250-5.
89. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Passas A, Linkesch W, Gouveia J, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887-93.
90. Morgenstern GR, Prentice AG, Prentice HG, Ropger JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies, U.K. multicentre antifungal prophylaxis study group. Br J Haematol 1999;105:901-11.
91. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
92. Boogaerts MA, Winston DJ, Bow EJ. A randomized controlled trial of intravenous and oral itraconazole versus intravenous amphotericin B for empirical antifungal therapy of persistent fever in neutropenic cancer patients receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001;135:412-22.